ATE152172T1 - Herstellung eines rekombinanten menschlichen interleukin-1-hemmers - Google Patents

Herstellung eines rekombinanten menschlichen interleukin-1-hemmers

Info

Publication number
ATE152172T1
ATE152172T1 AT91900515T AT91900515T ATE152172T1 AT E152172 T1 ATE152172 T1 AT E152172T1 AT 91900515 T AT91900515 T AT 91900515T AT 91900515 T AT91900515 T AT 91900515T AT E152172 T1 ATE152172 T1 AT E152172T1
Authority
AT
Austria
Prior art keywords
inhibitor
preparation
recombinant human
human interleukin
disclosed
Prior art date
Application number
AT91900515T
Other languages
English (en)
Inventor
Robert Hageman
Stephen P Eisenberg
David Dripps
Ronald Evans
Henryk Cudny
Robert C Thompson
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Application granted granted Critical
Publication of ATE152172T1 publication Critical patent/ATE152172T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT91900515T 1989-11-29 1990-11-29 Herstellung eines rekombinanten menschlichen interleukin-1-hemmers ATE152172T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44265289A 1989-11-29 1989-11-29

Publications (1)

Publication Number Publication Date
ATE152172T1 true ATE152172T1 (de) 1997-05-15

Family

ID=23757611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91900515T ATE152172T1 (de) 1989-11-29 1990-11-29 Herstellung eines rekombinanten menschlichen interleukin-1-hemmers

Country Status (17)

Country Link
US (1) US5453490A (de)
EP (1) EP0502956B1 (de)
JP (1) JP3014007B2 (de)
KR (1) KR0182819B1 (de)
AT (1) ATE152172T1 (de)
AU (1) AU651955B2 (de)
BR (1) BR9007883A (de)
CA (1) CA2068320C (de)
DE (1) DE69030582T2 (de)
DK (1) DK0502956T3 (de)
ES (1) ES2103305T3 (de)
FI (1) FI104733B (de)
GR (1) GR3024031T3 (de)
HK (1) HK1006856A1 (de)
HU (1) HUT64582A (de)
NO (1) NO305290B1 (de)
WO (1) WO1991008285A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5861476A (en) * 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ATE406176T1 (de) * 1996-12-06 2008-09-15 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
EP2087908B1 (de) 2001-06-26 2018-05-30 Amgen Inc. Antikörper gegen opgl
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2497884C (en) 2002-09-06 2013-10-22 Brian Varnum Therapeutic human anti-il-1r1 monoclonal antibody
HUE040595T2 (hu) 2004-04-02 2019-03-28 Swedish Orphan Biovitrum Ab Publ Eljárás IL-1ra aggregációjának csökkentésére
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
WO2009062339A1 (en) 2007-11-14 2009-05-22 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
EP2620139B1 (de) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1-Rezeptorantagonisten-reiche Lösungen
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
EP2598526B1 (de) 2010-07-29 2018-09-05 Eleven Biotherapeutics, Inc. Chimäre il-1 rezeptor typ i agonisten und antagonisten
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013019652A1 (en) * 2011-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Purified proteins
CN104302772B (zh) 2012-05-18 2017-11-10 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
DK2968468T3 (en) 2013-03-13 2021-07-26 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
CA2929201A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
EP3074507B1 (de) 2013-11-26 2022-01-05 Biomet Biologics, LLC Verfahren zur vermittlung von makrophagenphänotypen
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855747T2 (de) * 1987-08-26 1997-06-12 Biogen Inc Biologische materialien, deren herstellung und verwendung in der therapie
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
DE69131044T2 (de) * 1990-05-01 1999-11-18 Chiron Corp., Emeryville Interleukin-i antagonist und seine verwendung

Also Published As

Publication number Publication date
CA2068320A1 (en) 1991-05-30
HU9201777D0 (en) 1992-12-28
HK1006856A1 (en) 1999-03-19
CA2068320C (en) 2000-10-17
EP0502956A1 (de) 1992-09-16
DE69030582T2 (de) 1998-06-25
EP0502956B1 (de) 1997-04-23
AU651955B2 (en) 1994-08-11
NO922138D0 (no) 1992-05-29
EP0502956A4 (en) 1992-12-09
GR3024031T3 (en) 1997-10-31
FI104733B (fi) 2000-03-31
NO305290B1 (no) 1999-05-03
KR920703792A (ko) 1992-12-18
HUT64582A (en) 1994-01-28
JP3014007B2 (ja) 2000-02-28
KR0182819B1 (en) 1999-04-01
US5453490A (en) 1995-09-26
JPH05503007A (ja) 1993-05-27
FI922434A0 (fi) 1992-05-27
WO1991008285A1 (en) 1991-06-13
ES2103305T3 (es) 1997-09-16
FI922434A (fi) 1992-05-27
AU6900791A (en) 1991-06-26
BR9007883A (pt) 1992-09-29
NO922138L (no) 1992-05-29
DE69030582D1 (de) 1997-05-28
DK0502956T3 (da) 1997-10-20

Similar Documents

Publication Publication Date Title
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
PT822199E (pt) Polipeptidos monopegilados no terminal-n e metodo para a sua preparacao
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
IT8048102A0 (it) Procedimento di preparazione di un idrolisato di proteine purificato
NO900031D0 (no) Fremgangsmaate for fremstilling av olefiner ut fra naturgass.
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
YU108691A (sh) Nove 3,3'-ditiobis (propionske kiseline) i njihovi estri
NO902071L (no) Fremgangsmaate og mellomprodukter for fremstilling av oksoftalazinyl-eddiksyrer og analoger derav.
EP0378824A3 (en) Use of omega-3-fatty acids as anticachexia agents
IT8947842A0 (it) Procedimento per la produzione di r(+) amminocarnitina e s(-) amminocarnitina
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
IT9020860A0 (it) Procedimento per la depurazione fine di gas
AU3881889A (en) Human interferon-gamma, process to prepare said human interferon-gamma, and its use
AU7422387A (en) Tumor necrosis factor alpha as treatment for infectious diseases
IT8821211A0 (it) Processo per la preparazione di perfluoro (2 bromoetilviniletere).
IT1231506B (it) Procedimento per la purificazione di polieteri polioli.
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
IT8823099A0 (it) Nuovi analoghi retro-inversi della timopentina, il metodo per la loro sintesi ed il loro impiego per la preparazione di composizioni farmaceutiche
TH5761B (th) วิธีการเตรียมชิ้นกล้าสำหรับการเลี้ยงเนื้อเยื่อพืช
Greer Effects of NaCl on tobacco callus cultures
TH6648A (th) วิธีการเตรียมชิ้นกล้าสำหรับการเลี้ยงเนื้อเยื่อพืช
IT8819400A0 (it) Composizioni aminoacidiche perfezionate per il trattamento specifico delle insufficienze multiple d'organo.

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time